Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have earned a consensus rating of “Buy” from the seven analysts that are presently covering the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $25.40.

Several research analysts recently weighed in on SNDX shares. Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, December 7th. BTIG Research started coverage on shares of Syndax Pharmaceuticals in a research note on Friday, December 30th. They issued a “buy” rating and a $25.00 target price for the company. JMP Securities reissued a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, November 9th. Finally, Oppenheimer Holdings, Inc. set a $25.00 target price on shares of Syndax Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, January 26th.

Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) traded up 2.97% on Friday, reaching $11.10. 73,453 shares of the company were exchanged. Syndax Pharmaceuticals has a 1-year low of $6.31 and a 1-year high of $18.03. The company has a 50-day moving average price of $8.03 and a 200 day moving average price of $11.24. The stock’s market capitalization is $201.94 million.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/02/17/syndax-pharmaceuticals-inc-sndx-given-average-recommendation-of-buy-by-analysts.html

Several hedge funds and other institutional investors have recently bought and sold shares of SNDX. Kornitzer Capital Management Inc. KS increased its position in Syndax Pharmaceuticals by 13.8% in the second quarter. Kornitzer Capital Management Inc. KS now owns 45,500 shares of the company’s stock worth $448,000 after buying an additional 5,500 shares in the last quarter. Schwab Charles Investment Management Inc. bought a new position in Syndax Pharmaceuticals during the second quarter worth approximately $100,000. Tiverton Asset Management LLC increased its position in Syndax Pharmaceuticals by 1,329.8% in the third quarter. Tiverton Asset Management LLC now owns 123,136 shares of the company’s stock worth $1,867,000 after buying an additional 114,524 shares in the last quarter. Laurion Capital Management LP bought a new position in Syndax Pharmaceuticals during the third quarter worth approximately $305,000. Finally, Sphera Funds Management LTD. bought a new position in Syndax Pharmaceuticals during the third quarter worth approximately $2,521,000. 62.22% of the stock is owned by institutional investors.

“Syndax Pharmaceuticals, Inc. (SNDX) Given Average Recommendation of “Buy” by Analysts” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was copied illegally and republished in violation of US and international trademark & copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/02/17/syndax-pharmaceuticals-inc-sndx-given-average-recommendation-of-buy-by-analysts.html.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

5 Day Chart for NASDAQ:SNDX

Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.